WAT stock forecast, quote, news & analysis
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools... Show more
Waters Corporation (WAT) Stock Analysis: Merger Integration in Focus
Key Takeaways
- Waters Corporation recently completed a transformative combination with BD's Biosciences and Diagnostic Solutions businesses, boosting revenue scale but introducing integration challenges.
- Q1 2026 earnings due May 5, with consensus EPS of $2.31 and revenue around $1.2 billion expected.
- Analysts maintain a Moderate Buy consensus, with an average price target of $387.50, implying over 25% upside from recent levels.
- Shares have faced pressure in recent months, down approximately 19% year-to-date, amid broader market dynamics and merger-related caution.
- Core business shows resilience with projected 6.25% organic growth for 2026.
Current Market Snapshot
In recent weeks, Waters Corporation (WAT) stock has navigated volatility within its 52-week range, reflecting a mix of optimism around its expanded portfolio and caution over post-merger execution. Trading near the lower end of its yearly bounds, the shares have seen modest gains in the latest sessions amid anticipation for quarterly results. Broader pressures in the life sciences tools sector, coupled with macroeconomic sensitivities, have contributed to a year-to-date pullback of around 19%. However, elevated trading volumes and analyst support underscore potential resilience as the company integrates its recent acquisition and demonstrates core operational strength. Investor sentiment hinges on upcoming disclosures that could clarify near-term trajectories.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top performers from its library of over 350 AI trading bots, which deploy diverse strategies across thousands of tickers in stocks, ETFs, and crypto. These bots vary in timeframes—from 5 minutes to monthly—styles like momentum or mean reversion, and focus areas including semiconductors, data centers, small caps, and leveraged ETFs. Only the most suitable for prevailing market conditions earn a spot in this dynamic section, selected via AI analysis for real-time relevance and outperformance.
Standouts include bots with annualized returns ranging from 50% to 163%, win rates of 57% to 88%, and profit factors up to 7.12. For instance, a semiconductors-focused bot boasts +97% annualized return and 63% win rate over 8-day average holds, while small-cap strategies show +93% returns with 59% wins. Equipped with risk controls like 3% take-profit and 2% stop-loss corridors, they adapt to volatility through machine learning signals. Traders may explore these for automated insights tailored to current trends, complementing manual analysis.
Recent Developments Driving WAT Price Action
Waters Corporation (WAT) stock has been influenced by a series of events in the past 30 days, primarily centered on earnings anticipation and product advancements, against the backdrop of its February merger with BD's Biosciences and Diagnostic Solutions (BDS) businesses. The Q1 2026 earnings conference call, scheduled for May 5, has drawn focus, with analysts projecting EPS of $2.31 and revenue near $1.2 billion—a modest 2.7% EPS growth year-over-year. Pre-earnings positioning contributed to recent downside, including a 0.68% close on May 1, as investors weighed potential revisions amid the integrated BDS unit's softer initial performance.
Analyst updates added nuance: UBS maintained Neutral but cut its price target to $330 from $370 on April 13, citing integration risks; Evercore ISI upgraded to Outperform from In Line on April 6, highlighting long-term synergies; Barclays reiterated Buy on April 15; and Citi held Buy on April 7. These moves reflect a Moderate Buy consensus, with targets averaging $387.50. Shares outperformed peers on April 30 amid a strong session but underperformed on April 29 and 27, signaling choppy sentiment.
Product news provided positives: Waters debuted an industry-first Extended-Range Multi-Angle Light Scattering (MALS) detector, enhancing analytical capabilities for polymers and proteins. Additionally, FDA clearance for the Onclarity HPV Self-Collection Kit on April 8 advanced at-home cervical cancer screening, boosting shares that day. These innovations underscore strength in life sciences tools, where Waters holds leadership.
The BD merger, closed February 9 via Reverse Morris Trust, remains a pivotal driver. It added ~$3 billion in annual revenue potential for 2026, but shares dropped over 10% on close day due to BDS arriving softer than modeled, prompting a 7.8% slide on April 23 amid refocused concerns on near-term profits and integration. Full-year 2026 guidance targets $6.4-$6.46 billion revenue and 28.1% adjusted operating margin, with core organic growth at 6.25%. This expansion into diagnostics has heightened scale but amplified execution risks, contributing to a 19% three-month decline as investors digest the transformed profile.
2026 Outlook and Key Factors to Monitor
As Waters Corporation (WAT) progresses through 2026, the successful integration of BD's BDS unit will be paramount, with $3 billion in added revenue targeted alongside core organic growth of 6.25% driven by chemistry consumables and services. Investors should track progress on $6.4-$6.46 billion full-year revenue guidance and 28.1% margins, as synergies in diagnostics and life sciences discovery tools materialize.
Opportunities lie in rising demand for analytical instruments amid biopharma R&D expansion and precision diagnostics trends. Competitive positioning against peers like Thermo Fisher and Danaher could strengthen via innovations such as the new MALS detector. However, risks include BDS integration costs, potential delays in cost savings, and macroeconomic headwinds affecting capital spending in life sciences.
Regulatory approvals for expanded HPV testing and other workflows remain supportive, while broader industry shifts toward automation and sustainability will influence adoption. Monitoring quarterly execution, analyst revisions, and sector funding flows will provide clarity on sustained momentum in this enlarged entity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
WAT sees MACD Histogram just turned negative
WAT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on May 18, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for WAT moved out of overbought territory on May 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 67 cases where WAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 05, 2026. You may want to consider a long position or call options on WAT as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
WAT moved above its 50-day moving average on May 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for WAT crossed bullishly above the 50-day moving average on April 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .
WAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 230 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.133) is normal, around the industry mean (12.534). P/E Ratio (42.263) is within average values for comparable stocks, (92.891). Projected Growth (PEG Ratio) (1.475) is also within normal values, averaging (2.205). WAT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (5.754) is also within normal values, averaging (17.960).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis
Industry MedicalSpecialties